Comparative Study of the Tomey OA-2000, Tomey CASIA2, and the LenStar LS900
1 other identifier
observational
167
1 country
1
Brief Summary
This is a prospective comparative study that will be conducted at one clinical site in the United States, in which subjects who sign an informed consent form and fulfil all inclusion and exclusion criteria, will have OCT scans obtained using the test and the predicate devices. There will be two main types of analyses performed as part of this study, including 1) a precision analysis, and 2) an agreement analysis. The precision analyses will be conducted utilizing all complete complements of acceptable scans from the test devices and predicate device for each of the 3 configurations. A complete complement of acceptable scans can be defined as subjects having 3 acceptable replicate scans on each of the 3 devices, at each of the 3 configurations. This is also synonymous with 3 scans for each of the 3 configurations on all 3 devices. If subjects have more than 3 acceptable scans per configuration on a device, only the first 3 will be considered for analyses. The agreement analysis will be conducted utilizing the first set of acceptable scans from each instrument for all overlapping measurement types (for all measurement types two or more of the devices have in common) related to performance endpoints.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 23, 2023
CompletedFirst Submitted
Initial submission to the registry
September 12, 2023
CompletedFirst Posted
Study publicly available on registry
October 3, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2023
CompletedOctober 3, 2023
September 1, 2023
4 months
September 12, 2023
September 26, 2023
Conditions
Outcome Measures
Primary Outcomes (3)
Agreement between the test devices and predicate device
Agreement between each of the test devices and the predicate device will be evaluated by the mean difference and SD, the 95% limits of agreement (LOA), the Bland-Altman plots, and Deming regression for each subject population.
Through study completion, approximately 4 months
Precision of the test devices
A crossed two-way random-effects analysis of variance (ANOVA) model will be used to estimate the repeatability and reproducibility limits of each scan parameter by subject population and study device (test and predicate device). This ANOVA model will include the configuration, subject, and interaction between configuration and subject as the factors. Repeatability and reproducibility standard deviations, as well as the corresponding coefficient of variations (CVs), will be calculated using this ANOVA model.
Through study completion, approximately 4 months
Safety of the test devices
Adverse events reported will be listed by subject.
Through study completion, approximately 4 months
Study Arms (3)
Normal
Cataract
Special eye
Interventions
Optical measurements by optical biometers and an OCT
Eligibility Criteria
Normal subjects (22 years of age or older) Cataract subjects (22 years of age or older), Special eyes subjects (22 years of age or older)
You may qualify if:
- Male or female subjects 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed;
- Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date;
- Subjects who agree to participate in the study.
- Male or female subjects 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed;
- Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date;
- Subjects who agree to participate in the study;
- Subjects diagnosed with cataract classified per the LOCS III scale.
- Male or female subjects 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed;
- Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date;
- Subjects who agree to participate in the study;
- Subjects diagnosed with one or both eyes having aphakia, pseudophakia or silicone oil.
You may not qualify if:
- Subjects unable to tolerate ophthalmic imaging;
- Subjects who did not take off their contact lenses earlier than 15 minutes prior to the study;
- Subjects with any current ocular pathology, as determined by self-report and confirmed by the investigator assessment and/or confirmed by the investigator assessment at the study visit;
- Subjects that present with an active ocular infection in either eye;
- Subjects who have a history of ocular surgery, including laser therapy/surgery;
- Subjects with a condition or in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.
- Subjects unable to tolerate ophthalmic imaging;
- Subjects who did not take off their contact lenses earlier than 15 minutes prior to the study;
- Subjects with corneal or conjunctival abnormalities that may affect adequate assessment of the anterior chamber in either eye;
- Subjects that present with an active ocular infection in either eye;
- Subjects who have a history of ocular surgery, including laser therapy/surgery;
- Subjects with a condition or in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.
- Subjects unable to tolerate ophthalmic imaging;
- Subjects who did not take off their contact lenses earlier than 15 minutes prior to the study;
- Subjects with corneal or conjunctival abnormalities that may affect adequate assessment of the anterior chamber in either eye;
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
NorthEast Eye Research Associates
Woburn, Massachusetts, 01801, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ioanis Panagiotopoulos, Dr.
NorthEast Eye Research Associates
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 12, 2023
First Posted
October 3, 2023
Study Start
June 23, 2023
Primary Completion
October 31, 2023
Study Completion
October 31, 2023
Last Updated
October 3, 2023
Record last verified: 2023-09